Cencora, Inc. $COR Shares Bought by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 3.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 65,443 shares of the company’s stock after purchasing an additional 1,958 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Cencora were worth $20,283,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Kemnay Advisory Services Inc. acquired a new position in Cencora during the 4th quarter valued at about $25,000. Oakworth Capital Inc. acquired a new stake in shares of Cencora in the 4th quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora in the 4th quarter worth approximately $27,000. Archer Investment Corp boosted its holdings in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after acquiring an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC bought a new position in shares of Cencora in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $307.72 on Monday. The firm’s 50 day moving average is $279.98 and its 200-day moving average is $317.52. The stock has a market capitalization of $59.87 billion, a P/E ratio of 23.60, a P/E/G ratio of 1.71 and a beta of 0.58. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the prior year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora announced that its Board of Directors has approved a stock repurchase plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 3.9% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio is 18.40%.

Insider Buying and Selling at Cencora

In related news, Director Lauren M. Tyler acquired 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The stock was acquired at an average cost of $270.23 per share, with a total value of $148,626.50. Following the purchase, the director directly owned 4,359 shares in the company, valued at $1,177,932.57. The trade was a 14.44% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.38% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

COR has been the topic of a number of research analyst reports. Wells Fargo & Company lowered their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Weiss Ratings downgraded Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. Citigroup decreased their price target on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Bank of America lifted their price target on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Finally, Robert W. Baird dropped their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.